Recipharm Advanced Bio
Stockholm, Sweden
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
63.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (11)
○ EMA GMP
○ MHRA GMP
Quick Facts: Recipharm Advanced Bio
- Signal Score
- 63.0/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Stockholm, Sweden
- Modalities
- AAV, Lentiviral, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Recipharm Advanced Bio
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
68.0
Parent company: Recipharm
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Recipharm
Financial assessment: 68.0/100
Capacity
58.0
1 manufacturing site: Stockholm, SE
Modalities: AAV, Lentiviral, Cell Therapy
Capacity assessment: 58.0/100
Sites: Stockholm, SE
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals11 articles (not scored)
1 manufacturing site: Stockholm, SE
Modalities: AAV, Lentiviral, Cell Therapy
Capacity assessment: 58.0/100
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (36 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the Recipharm Personio board covers Wasserburg only, none of the Advanced Bio sites. We'd rather show no number than one that isn't really this company's.
Source:
personio
· Checked Nov 20, 2026
Company Signals 11 articles
Company announcements, not verified evidence. They do not change any score.
Recipharm shutters Boxborough facility, cuts local workforce 40% - Worcester Business Journal
Recipharm shutters Boxborough facility, cuts local workforce 40% Worcester Business Journal
Change at the top at Recipharm as strategy shifts - pharmaphorum
Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership - Fierce Pharma
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - PR Newswire
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - PR Newswire
Recipharm makes major investment to expand US sterile manufacturing footprint - European Pharmaceutical Review
Recipharm channels ‘multi-million-dollar' US manufacturing upgrade, targeting domestic biologics demand - Fierce Pharma
Recipharm and Exela Pharma Sciences Form Exclusive CDMO Strategic Alliance - Genetic Engineering and Biotechnology News
Recipharm bolsters fill/finish capacity at German site - BioProcess International
LGC opens $72M chemical plant; Recipharm partners with NeuroSense - Endpoints News
Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs - Fierce Pharma
Frequently Asked Questions About Recipharm Advanced Bio
What is Recipharm Advanced Bio's CDMO Signal Score?
Recipharm Advanced Bio has a Signal Score of 63/100, based on quality, operations, financial stability, and capacity data.
Evaluating Recipharm Advanced Bio for a manufacturing program?
Use the free AI matchmaker to compare Recipharm Advanced Bio against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
Signal Score: 79.5
Viral Vectors, AAV, Lentiviral, Adenoviral, HPAPIs, Small Molecules, Peptides, BioCatalysis, Chromatography, Cell Therapy
NecstGen
Leiden, NL
Signal Score: 78.1
AAV, Lentiviral, Cell Therapy
Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
Compare Recipharm Advanced Bio with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.